Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE versus MARCAINE HYDROCHLORIDE W EPINEPHRINE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE versus MARCAINE HYDROCHLORIDE W EPINEPHRINE PRESERVATIVE FREE.
LABETALOL HYDROCHLORIDE vs MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a non-selective beta-adrenoceptor blocker and selective alpha-1 adrenoceptor blocker. It reduces myocardial contractility, heart rate, and peripheral vascular resistance.
Bupivacaine blocks sodium ion channels on the neuronal membrane, inhibiting depolarization and conduction of nerve impulses. Epinephrine causes local vasoconstriction, delaying absorption and prolonging anesthetic effect.
Oral: Initial 100 mg twice daily, titrate up to 200-400 mg twice daily; maximum 2400 mg/day. IV: 20 mg slow IV over 2 minutes, then 40-80 mg every 10 minutes as needed up to 300 mg total; or continuous IV infusion at 0.5-2 mg/min.
Local infiltration: up to 30 mL of 0.25% (75 mg) or 0.5% (150 mg) solution. Epidural (lumbar): 10-20 mL of 0.5% (50-100 mg) with 1:200,000 epinephrine, repeated every 1.5-3 hours as needed. Maximum single dose: 225 mg (with epinephrine 1:200,000).
None Documented
None Documented
Terminal elimination half-life: 6-8 hours. In renal impairment, half-life may be slightly prolonged but not clinically significant; in hepatic impairment, half-life may be significantly prolonged.
Terminal half-life of bupivacaine is 2.7–4.2 hours in adults; prolonged to 8–12 hours in neonates and patients with hepatic impairment.
Primarily hepatic metabolism; ~5% excreted unchanged in urine; ~55-60% as glucuronide conjugates in urine; fecal excretion <5%.
Primarily hepatic metabolism via CYP3A4 and amide hydrolysis; <5% excreted unchanged in urine. Biliary excretion accounts for <2% of total elimination.
Category A/B
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist